Comparison of AmnioFix Laser and Standard of Care Treatment

Rhytides Clinical Trial

Official title:

Comparison of AmnioFix Laser and Standard of Care in Patients Seeking Laser Facial Treatment

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02659124
• Other study ID #: AmnioFix Laser Study
• Status: Withdrawn
• Phase: N/A
• Est. completion date: January 2018

Study information

• Verified date: March 2022
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a comparison trial with novel application of AmnioFix and a control arm. Patients electively being treated with facial lasers will be assigned to receive AmnioFix in addition to the normal standard of care placed on half of their face after laser procedure, and normal post laser standard of care alone on the other half of their face. The investigators will investigate the end points of healing, recovery time, re-epitheliaziation, and other cosmetic factors. The study is designed to compare AmnioFix to the current standard of laser care.

Description:

AmnioFix is a dehydrated Human Amnion/ Chorion Membrane (dHACM) allograft and is composed of multiple layers including a single layer of epithelial cells, a basement membrane and an avascular connective tissue matrix. Amniotic membrane is a unique material and its composition contains collagen types I, III, IV, V, and VII. Amniotic membrane is composed of structural extracellular matrix (ECM), that also contains specialized proteins fibronectin, laminins, proteoglycans and glycosaminoglycans. In addition, amniotic membrane contains essential, active, healing growth factors such as epidermal growth factor (EGF), transforming growth factor beta (TGF-b), fibroblast growth factor (FGF), and platelet derived growth factor (PDGF).

The study is designed to compare AmnioFix to the current standard of laser care.

• Patients coming in for fraction or total ablative resurfacing with any methods will be studied

• patients will be assessed prior to any treatment by clinician

• additionally patients will participate in a clinician constructed survey

• patients will be assessed on a rating scale of 1-4 based on erythema, edema/induration, oozing/drainage, and epithelialization

• preoperative photos will be taken of patients

• laser resurfacing will proceed under clinician guidance, and under clinician selected settings

• repeat photographs

• patients will be randomized as to which side of the face receives AmnioFix treatment, and which side receives standard of care

• epifix will be applied appropriatly

• repeat photographs and repeat assessment on 1-4 scale

• patients will follow up at day 1, 4, 7, 14, and 28 +/-3 days to repeat scoring and photography

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: January 2018
• Est. primary completion date: April 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• adult patients ages 18-100 seeking laser facial treatment

Exclusion Criteria:

• patients with treatment areas with active or latent infection

• patient with a disorder that would create an unacceptable risk of post-operative complications

Related Conditions & MeSH terms

• Rhytides

Intervention

Device:
• AmnioFix plus Standard of Care
Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.

Procedure:
• Standard of Care
Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.

Locations

Country	Name	City	State
United States	UCSF Dermatology	San Francisco	California

Sponsors (1)

Lead Sponsor	Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Time of reepithelialization	Subjects' healing and recovery is the primary outcome measure. Reepithelialization will be assessed at each follow up visit, considering the following: erythema, edema/induration, and oozing/drainage.	28 days after treatment